The value of the systematic inflammation-based Glasgow Prognostic Score in patients with gastric cancer: A literature review

被引：37
作者：
Gao, Yongyin [1 ]
Huang, Dingzhi [1 ]
机构：
[1] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Gastrointestinal Med Oncol, Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China
来源：
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS | 2014年 / 10卷 / 04期
关键词：
Gastric cancer; glasgow prognostic score; modified glasgow prognostic score; the prognostic value; CELL LUNG-CANCER; PERFORMANCE STATUS ECOG; TO-LYMPHOCYTE RATIO; PALLIATIVE CHEMOTHERAPY; GASTROESOPHAGEAL CANCER; CURATIVE RESECTION; SURVIVAL; TUMOR; HYPOALBUMINEMIA; GPS;
D O I：
10.4103/0973-1482.146054
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The presence of a systemic inflammatory response (SIR) is recognized to occur in the presence of malignancy. And the SIR-Glasgow Prognostic Score (GPS)/modified GPS (mGPS) composed of the C-reactive protein (CRP) and albumin is a tumor stage- and treatment-independent, routinely available and well-standardized prognostic factor, reflects both an ongoing SIR (CRP) and a progressive nutritional decline (albumin) in patients with advanced cancer. Previous studies showed that GPS/mGPS appear to be a superior prognostic factor compared with other cellular components of the SIR and Eastern Cooperative Oncology Group performance status in some aspects. Besides, GPS/mGPS aids at deciding active or palliation treatment and selecting patients with gastric cancer who tolerate platinum-based chemotherapy. Therefore, GPS/mGPS may be incorporated or combined with other factors to improve assessment of prognosis and guide treatment of patients with gastric cancer in a routine clinical work. However, it remains to be determined whether the GPS and mGPS have different prognostic value in each stage of gastric cancer and the necessity of normalization of the GPS/mGPS by anti-inflammation and maintenance of performance status or nutritional status in clinical work.
引用
收藏
页码：799 / 804
页数：6
相关论文
共 30 条
[1]   Gastric Cancer, Version 2.2013 Featured Updates to the NCCN Guidelines [J].
Ajani, Jaffer A. ;
Bentrem, David J. ;
Besh, Stephen ;
D'Amico, Thomas A. ;
Das, Prajnan ;
Denlinger, Crystal ;
Fakih, Marwan G. ;
Fuchs, Charles S. ;
Gerdes, Hans ;
Glasgow, Robert E. ;
Hayman, James A. ;
Hofstetter, Wayne L. ;
Ilson, David H. ;
Keswani, Rajesh N. ;
Kleinberg, Lawrence R. ;
Korn, W. Michael ;
Lockhart, A. Craig ;
Meredith, Kenneth ;
Mulcahy, Mary F. ;
Orringer, Mark B. ;
Posey, James A. ;
Sasson, Aaron R. ;
Scott, Walter J. ;
Strong, Vivian E. ;
Varghese, Thomas K., Jr. ;
Warren, Graham ;
Washington, Mary Kay ;
Willett, Christopher ;
Wright, Cameron D. ;
McMillian, Nicole R. ;
Sundar, Hema .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2013, 11 (05) :531-546
[2]   The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases [J].
Al-Shaiba, R ;
McMillan, DC ;
Angerson, WJ ;
McArdle, CS ;
Horgan, P .
BRITISH JOURNAL OF CANCER, 2004, 91 (02) :205-207
[3]   Value of Preoperative Inflammation-Based Prognostic Scores in Predicting Overall Survival and Disease-Free Survival in Patients with Gastric Cancer [J].
Aurello, Paolo ;
Tierno, Simone Maria ;
Berardi, Giammauro ;
Tomassini, Federico ;
Magistri, Paolo ;
D'Angelo, Francesco ;
Ramacciato, Giovanni .
ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (06) :1998-2004
[4]   Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial [J].
Bang, Yung-Jue ;
Van Cutsem, Eric ;
Feyereislova, Andrea ;
Chung, Hyun C. ;
Shen, Lin ;
Sawaki, Akira ;
Lordick, Florian ;
Ohtsu, Atsushi ;
Omuro, Yasushi ;
Satoh, Taroh ;
Aprile, Giuseppe ;
Kulikov, Evgeny ;
Hill, Julie ;
Lehle, Michaela ;
Ruschoff, Josef ;
Kang, Yoon-Koo .
LANCET, 2010, 376 (9742) :687-697
[5]   Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer [J].
Crumley, ABC ;
McMillan, DC ;
McKernan, M ;
McDonald, AC ;
Stuart, RC .
BRITISH JOURNAL OF CANCER, 2006, 94 (05) :637-641
[6]   Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG-ps) in patients receiving palliative chemotherapy for gastroesophageal cancer [J].
Crumley, Andrew B. C. ;
Stuart, Robert C. ;
McKernan, Margaret ;
McDonald, Alexander C. ;
McMillan, Donald C. .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2008, 23 (08) :E325-E329
[7]   Is Hypoalbuminemia an Independent Prognostic Factor in Patients with Gastric Cancer? [J].
Crumley, Andrew B. C. ;
Stuart, Robert C. ;
McKernan, Margaret ;
McMillan, Donald C. .
WORLD JOURNAL OF SURGERY, 2010, 34 (10) :2393-2398
[8]   Immune cells as mediators of solid tumor metastasis [J].
DeNardo, David G. ;
Johansson, Magnus ;
Coussens, Lisa M. .
CANCER AND METASTASIS REVIEWS, 2008, 27 (01) :11-18
[9]   Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancer [J].
Dutta, Sumanta ;
Crumley, Andrew B. C. ;
Fullarton, Grant M. ;
Horgan, Paul G. ;
McMillan, Donald C. .
AMERICAN JOURNAL OF SURGERY, 2012, 204 (03) :294-299
[10]   Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer [J].
Forrest, LM ;
McMillan, DC ;
McArdle, CS ;
Angerson, WJ ;
Dunlop, DJ .
BRITISH JOURNAL OF CANCER, 2004, 90 (09) :1704-1706
123